The relationship between KRAS gene mutations in colorectal cancer patients and the response to chemotherapy with a 5-fluorouracil and oxaliplatin regimen at Dr. Moewardi General Hospital
DOI:
https://doi.org/10.18203/2349-2902.isj20262444Keywords:
Colorectal cancer, KRAS mutation, Chemotherapy, 5-fluorouracil, OxaliplatinAbstract
Background: Colorectal cancer remains a significant cause of mortality worldwide. While KRAS gene mutations are established predictors of resistance to anti-EGFR targeted therapy, their impact on response to conventional chemotherapy involving 5-fluorouracil (5-FU) and oxaliplatin remains inconsistent. This study aimed to evaluate the relationship between KRAS mutation status and the clinical response to 5-FU and oxaliplatin-based chemotherapy in colorectal cancer patients at Dr. Moewardi General Hospital.
Methods: This was an observational analytic study utilizing a retrospective cohort design. The sample included 48 colorectal cancer patients who underwent 5-FU and oxaliplatin chemotherapy with documented KRAS mutation status. Data were extracted from medical records, encompassing demographics, mutation status, chemotherapy response, TNM stage, metastasis, and mortality. Bivariate analysis was performed using the Fisher Freeman–Halton exact test, and multivariate analysis was conducted via binary logistic regression.
Results: Most patients were aged 50–59 years (33.3%) and were female (62.5%). KRAS mutations were found in 66.7% of patients. Chemotherapy response was predominantly progressive disease (75%). Among KRAS-positive patients, 78.1% experienced progressive disease. Bivariate analysis showed no significant association between KRAS mutation status and chemotherapy response (p=0.679). Logistic regression analysis also did not identify any factors that significantly affected mortality.
Conclusions: There was no statistically significant association between KRAS gene mutation status and the response to 5-FU and oxaliplatin chemotherapy in colorectal cancer patients within this study population.
References
Dekker E, Tanis PJ, Vleugels JLA, Kasi PM, Wallace MB. Colorectal cancer. Lancet. 2019;394(10207):1467-80.
Gandomani HS, Aghajani M, Mohammadian-Hafshejani A, Tarazoj AA, Pouyesh V, Salehiniya H. Colorectal cancer in the world: incidence, mortality and risk factors. Biomed Res Ther. 2017;4(10):1656-75.
Mármol I, Sánchez-de-Diego C, Dieste AP, Cerrada E, Yoldi MJR. Colorectal Carcinoma: A General Overview and Future Perspectives in Colorectal Cancer. Int J Mol Sci. 2017;18(1).
Hossain MS, Karuniawati H, Jairoun AA, Urbi Z, Ooi DJ, John A, et al. Colorectal Cancer: A Review of Carcinogenesis, Global Epidemiology, Current Challenges, Risk Factors, Preventive and Treatment Strategies. Cancers. 2022;14:1732.
Khairina D, Suzanna E, Triana D, Kadir A, Widyastuti TH, Sulistyowati LS, et al. Profile of Colorectal Cancer in 14 Provinces in Indonesia. J Glob Oncol. 2018;4(Suppl 2):66s.
Rawla P, Sunkara T, Barsouk A. Epidemiology of colorectal cancer: Incidence, mortality, survival, and risk factors. Prz Gastroenterol. 2019;14(2):89-103.
Barresi V. Colorectal cancer: From pathophysiology to novel therapeutic approaches. Biomedicines. 2021;9(12):1858.
Duan B, Zhao Y, Bai J, Wang J, Duan X, Luo X, Zhang R. Colorectal Cancer: An Overview. Exon Publications. 2022.
Rawl SM, Menon U, Burness A, Breslau ES. Interventions to promote colorectal cancer screening: an integrative review. Nurs Outlook. 2012;60(4):172-81.
Issa IA, NouredDine M. Colorectal cancer screening: An updated review of the available options. World J Gastroenterol. 2017;23(28):5086-96.
Li J, Yi CH, Hu YT, Li JS, Yuan Y, Zhang SZ, et al. TNM Staging of Colorectal Cancer Should be Reconsidered According to Weighting of the T Stage. Medicine (Baltimore). 2016;95(6):1-8.
Sari MI, Wahid I, Suchitra A. Kemoterapi Adjuvan pada Kanker Kolorektal. Jurnal Kesehatan Andalas. 2019;8(1S):51.
Devanabanda B, Kasi A. Oxaliplatin. NCBI Bookshelf. 2023.
Fukuchi M, Ishibashi K, Tajima Y, Okada N, Yokoyama M, Chika N, et al. Oxaliplatin-based chemotherapy in patients aged 75 years or older with metastatic colorectal cancer. Anticancer Res. 2013;33(10):4627-30.
Iyer JG, Blom A, Doumani R, Lewis C, Tarabadkar ES, Anderson A, et al. Response rates and durability of chemotherapy among 62 patients with metastatic Merkel cell carcinoma. Cancer Med. 2016;5(9):2294-301.
Arrington AK, Heinrich EL, Lee W, Duldulao M, Patel S, Sanchez J, et al. Prognostic and Predictive Roles of KRAS Mutation in Colorectal Cancer. Int J Mol Sci. 2012;13(10):12153-68.
Meng M, Zhong K, Jiang T, Liu Z, Kwan HY, Su T. The current understanding on the impact of KRAS on colorectal cancer. Biomed Pharmacother. 2021;140:111717.
Huang L, Guo Z, Wang F, Fu L. KRAS mutation: from undruggable to druggable in cancer. Signal Transduct Target Ther. 2021;6(1):1-20.
Porru M, Pompili L, Caruso C, Biroccio A, Leonetti C. Targeting KRAS in metastatic colorectal cancer: Current strategies and emerging opportunities. Mol Cancer. 2021;20:1-15.
Fornasier G, Francescon S, Baldo P. An Update of Efficacy and Safety of Cetuximab in Metastatic Colorectal Cancer: A Narrative Review. Adv Ther. 2018;35(10):1497-509.
Ji J, Wang C, Fakih M. Targeting KRAS G12C-Mutated Advanced Colorectal Cancer: Research and Clinical Developments. OncoTargets Ther. 2022;15:747-56.
Liu G, Tu D, Lewis M, Cheng D, Sullivan LA, Chen Z, et al. Fc-γ receptor polymorphisms, cetuximab therapy, and survival in the NCIC CTG CO.17 trial of colorectal cancer. Clin Cancer Res. 2016;22(10):2435-44.
Dobre M, Elena Dinu D, Panaitescu E, Daniela Bîrlă R, Iosif C, Boeriu M, et al. KRAS gene mutations-prognostic factor in colorectal cancer? Rom J Morphol Embryol. 2015;56(2):671-8.
Li ZN, Zhao L, Yu LF, Wei MJ. BRAF and KRAS mutations in metastatic colorectal cancer: future perspectives for personalized therapy. Gastroenterol Rep. 2020;8(3):192-205.
Downloads
Published
How to Cite
Issue
Section
